Incyte Corporation (Nasdaq:INCY) announced today that its Board of Directors has greenlit a $2.0 billion share repurchase program. As part of this initiative, the company has initiated a modified “Dutch Auction” tender offer, aiming to buy back shares of its…
Eisai announced today that it has received approval in China for an additional indication of its antiepileptic drug (AED) Fycompa® (generic name: perampanel hydrate) for adjunctive treatment of primary generalized tonic-clonic seizures in patients aged 12 years and older. Fycompa…
Revelation Biosciences, Inc. (NASDAQ: REVB), a clinical-stage life sciences firm dedicated to leveraging trained immunity for disease prevention and treatment, released its financial results for the three months ending March 31, 2024. Financial Highlights: As of March 31, 2024, the…
Today, governments worldwide have reaffirmed their commitment to advancing a proposed pandemic agreement, aiming to refine the draft in preparation for the Seventy-seventh World Health Assembly commencing on May 27, 2024. At the World Health Organization headquarters in Geneva, government…
Viatris has just announced its financial outcomes for the initial quarter of 2024, showcasing sustained progress and the robustness of its core operations. Executive Insights Scott A. Smith, CEO of Viatris, remarked, “Our impressive financial results for the first quarter…
argenx, a global leader in immunology dedicated to enhancing the lives of individuals grappling with severe autoimmune disorders, has unveiled its financial results for the first quarter of 2024 along with a comprehensive business update. Tim Van Hauwermeiren, Chief Executive…
BeiGene, a leading global oncology firm, has unveiled its first-quarter 2024 results alongside significant business updates. John V. Oyler, Co-Founder, Chairman, and CEO at BeiGene, expressed satisfaction with the robust financial performance, citing substantial revenue growth propelling the company into…
Lupin, a leading pharmaceutical company, has recently welcomed two distinguished individuals, Mr. Jeffrey Kindler and Mr. Alfonso “Chito” Zulueta, to its Board as Independent Directors. Mr. Kindler boasts an illustrious career as a healthcare executive, investor, and advisor, accumulating over…
Revolution Medicines, Inc. (Nasdaq: RVMD), a company focused on developing targeted therapies for patients with RAS-addicted cancers, has disclosed its financial results for the quarter ending March 31, 2024, alongside an update on its corporate advancements. The company’s strides in…
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced its consolidated financial performance for the first quarter ended March 31, 2024, while reaffirming its full-year 2024 financial outlook. Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex, expressed satisfaction with the robust…
AstraZeneca has confirmed the successful conclusion of its equity investment agreement with Cellectis, a clinical-stage biotech firm. The investment, along with a research collaboration deal unveiled in November 2023, aims to harness Cellectis’ proprietary gene editing technologies and manufacturing capabilities…
UroGen Pharma Ltd. (Nasdaq: URGN) has unveiled significant findings from a sub-analysis within the largest real-world patient cohort evaluation of JELMYTO (mitomycin) for pyelocalyceal solution, presented at the American Urological Association Meeting 2024 in San Antonio, TX. This analysis focused…